Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EPI-743

PreclinicalSmall molecule

EEdison Pharmaceuticals Inc

EPI-743 is one of 22 small molecule programs targeting Neuropathy. It is currently in Preclinical.

1

Indications

13

Total Trials

0

Active Trials

21

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuropathyActive, not recruiting

NeuropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Neuropathy

#DrugCompanyPhaseTrials

Elavil

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Accupril

Pamelor

Mexitil

Boehringer Ingelheim

Epsom Salt

FFresenius Kabi USA, LLC

Immunoglobulin

Rituxan

Calquence

Calciferol

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ataxia2 trials

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

Completed·PPTC Therapeutics·Phase 2·NCT01728064·60 enrolled

EPI-743 in Friedreich's Ataxia Point Mutations

Completed·UUniversity of South Florida·Phase 2·NCT01962363·4 enrolled

Mitochondria2 trials

EPI-743 for Metabolism or Mitochondrial Disorders

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 1/2·NCT01642056·20 enrolled

EPI-743 for Mitochondrial Respiratory Chain Diseases

No longer available·PPTC Therapeutics··NCT01370447

Parkinson's Disease1 trial

A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease

Completed·UUniversity of South Florida·Phase 2·NCT01923584·15 enrolled

Autism Spectrum Disorder1 trial

An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

Withdrawn·EEdison Pharmaceuticals Inc·Phase 2·NCT02226458

Rett syndrome1 trial

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

Completed·EEdison Pharmaceuticals Inc·Phase 2·NCT01822249·24 enrolled

6 more indications

Tourette syndrome1 trial

Open-Trial of EPI-743 for Adults With Tourette Syndrome

Completed·YYale University·Phase 1·NCT01719523·10 enrolled

Impairment1 trial

EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment

Completed·—·Phase 2·NCT01793090·30 enrolled

Leigh syndrome1 trial

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Completed·PPTC Therapeutics·Phase 2·NCT02352896·30 enrolled

Noise-Induced Hearing Loss1 trial

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

Completed·EEdison Pharmaceuticals Inc·Phase 2·NCT02257983·77 enrolled

Children1 trial

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

Terminated·EEdison Pharmaceuticals Inc·Phase 2·NCT02104336·2 enrolled

Neuropathy1 trial

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

No longer available·EEdison Pharmaceuticals Inc··NCT02300753

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for EPI-743. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EPI-743 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EPI-743. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Edison Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEdison Pharmaceuticals Inc

Related News